New Targeted Therapies Show Promise for Resistant GIST
Patients with resistant GIST may have more treatment options as new targeted therapies show improved response rates in trials.
Updated on Oct. 26, 2026 in Cancer
Live Poll
Does new molecular biomarker research improve the chances of identifying successful cancer treatment plans?
Clinical trials reported positive outcomes for several new, investigational treatments targeting imatinib-resistant gastrointestinal stromal tumors (GIST). These therapies, including bezuclatinib and NB003, aim to improve survival rates for patients whose disease has progressed on standard treatments.
Why it matters
GIST management is complex once tumors develop resistance to first-line therapies like imatinib, necessitating new options that cover a broader range of KIT mutations. These findings highlight progress in developing targeted combinations and biomarkers to guide future clinical decision-making.
These preliminary clinical findings report objective response rates for novel KIT inhibitors and combination therapies in patients with resistant GIST. While NB003 showed a 46.7% response rate in third-line patients, 84% experienced Grade 3 or higher treatment-related adverse events.
The details
These investigational therapies function by targeting primary and secondary KIT mutations that drive tumor growth in resistant GIST. Bezuclatinib combined with sunitinib acts by covering a broader spectrum of these mutations, while velzatinib is designed to inhibit an array of resistance mutations. Researchers are also evaluating circulating tumor DNA (ctDNA) clearance as a predictive biomarker, finding that mutant KIT reduction at week 8 correlates with improved progression-free survival.
Timeline
Week 8: Assessment of mutant KIT ctDNA clearance for predictive clinical outcomes.
Health Landscape
The treatment of GIST is currently evolving from generic tyrosine kinase inhibitors toward more precise, mutation-specific targeted therapies. These findings help define the next generation of care following the StrateGIST 3 trial and other ongoing investigations into early-line combinations.
Patients currently managing resistant GIST should consult with an oncologist regarding the availability of clinical trials like StrateGIST 3 or SynerGIST-1st Line. It is important to discuss potential side effects and the role of mutation testing in determining eligibility for these investigational treatments.
The takeaway
Advancements in targeted GIST therapies offer hope for patients facing resistance to current standards, but these treatments often carry significant risks. Keep track of your mutational profile and consult your physician to determine if emerging clinical trials represent a viable path for your care.
Further reading
For more on evolving research, visit our Cancer hub.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Does new molecular biomarker research improve the chances of identifying successful cancer treatment plans?
